Skip to main content
. 2019 Jun 25;6(3):421–433. doi: 10.1007/s40744-019-0162-6

Fig. 1.

Fig. 1

Patient disposition. aThe 12-month follow-up visit occurred in a window of 9–15 months. bThe 6-month follow-up visit occurred in a window of 3–9 months. Patients with a visit outside of the 3- to 9-month window or patients without prednisone dose information available at the 6-month (± 3 months) visit were excluded. csDMARD conventional synthetic disease-modifying antirheumatic drug, TCZ tocilizumab